Renal 25-hydroxyvitamin D3-1-hydroxylase in patients with renal disease. 1988

K Satomura, and Y Seino, and K Yamaoka, and Y Tanaka, and M Ishida, and H Yabuuchi, and Y Tanaka, and H F DeLuca
Department of Pediatrics, Osaka University Hospital, Osaka University School of Medicine, Japan.

Renal 25-hydroxyvitamin D3-1-hydroxylase (1-hydroxylase) activity has been measured in 20 patients with renal disease using the remaining portion of needle renal biopsy specimens taken for diagnostic purposes and in five patients using kidney tissue removed during transplantation. The 1-hydroxylase activity of 12 patients with asymptomatic proteinuria and/or hematuria (group A) measured 83.2 +/- 37.7 pg/mg tissue/20 min. Since these 12 patients did not show impaired mineral metabolism or pathological changes in the renal tubules, we have presumed that these results indicate normal activity in man. We also measured the 1-hydroxylase activity in four patients treated with prednisolone (group B). The 1-hydroxylase activity (81.1 +/- 27.1 pg/mg tissue/20 min) of group B did not differ from that of group A. However, the urinary excretion of calcium (ratio of calcium/creatinine) was increased (0.18 +/- 0.07 vs. 0.07 +/- 0.03, P less than 0.01) by prednisolone therapy. These data suggest that glucocorticoid-induced changes in urinary calcium excretion are not the result of a direct effect of glucocorticoid on renal 1-hydroxylase. In the three patients with mild renal insufficiency (group C), the 1-hydroxylase activity (75.4 +/- 22.4 pg/mg tissue/20 min) did not differ from that of group A. However, in five patients with severe renal insufficiency (group D), the 1-hydroxylase activity (8.5 +/- 3.7 pg/mg tissue/20 min) was significantly decreased (P less than 0.01).

UI MeSH Term Description Entries
D007668 Kidney Body organ that filters blood for the secretion of URINE and that regulates ion concentrations. Kidneys
D007674 Kidney Diseases Pathological processes of the KIDNEY or its component tissues. Disease, Kidney,Diseases, Kidney,Kidney Disease
D007676 Kidney Failure, Chronic The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION. ESRD,End-Stage Renal Disease,Renal Disease, End-Stage,Renal Failure, Chronic,Renal Failure, End-Stage,Chronic Kidney Failure,End-Stage Kidney Disease,Chronic Renal Failure,Disease, End-Stage Kidney,Disease, End-Stage Renal,End Stage Kidney Disease,End Stage Renal Disease,End-Stage Renal Failure,Kidney Disease, End-Stage,Renal Disease, End Stage,Renal Failure, End Stage
D008297 Male Males
D011239 Prednisolone A glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. Di-Adreson-F,Predate,Predonine,Di Adreson F,DiAdresonF
D012016 Reference Values The range or frequency distribution of a measurement in a population (of organisms, organs or things) that has not been selected for the presence of disease or abnormality. Normal Range,Normal Values,Reference Ranges,Normal Ranges,Normal Value,Range, Normal,Range, Reference,Ranges, Normal,Ranges, Reference,Reference Range,Reference Value,Value, Normal,Value, Reference,Values, Normal,Values, Reference
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths

Related Publications

K Satomura, and Y Seino, and K Yamaoka, and Y Tanaka, and M Ishida, and H Yabuuchi, and Y Tanaka, and H F DeLuca
January 1980, Methods in enzymology,
K Satomura, and Y Seino, and K Yamaoka, and Y Tanaka, and M Ishida, and H Yabuuchi, and Y Tanaka, and H F DeLuca
March 2002, Nihon rinsho. Japanese journal of clinical medicine,
K Satomura, and Y Seino, and K Yamaoka, and Y Tanaka, and M Ishida, and H Yabuuchi, and Y Tanaka, and H F DeLuca
August 1990, The American journal of physiology,
K Satomura, and Y Seino, and K Yamaoka, and Y Tanaka, and M Ishida, and H Yabuuchi, and Y Tanaka, and H F DeLuca
March 2007, The Journal of steroid biochemistry and molecular biology,
K Satomura, and Y Seino, and K Yamaoka, and Y Tanaka, and M Ishida, and H Yabuuchi, and Y Tanaka, and H F DeLuca
December 1974, The Journal of biological chemistry,
K Satomura, and Y Seino, and K Yamaoka, and Y Tanaka, and M Ishida, and H Yabuuchi, and Y Tanaka, and H F DeLuca
May 1999, Molecular and cellular endocrinology,
K Satomura, and Y Seino, and K Yamaoka, and Y Tanaka, and M Ishida, and H Yabuuchi, and Y Tanaka, and H F DeLuca
January 1982, Endocrinology,
K Satomura, and Y Seino, and K Yamaoka, and Y Tanaka, and M Ishida, and H Yabuuchi, and Y Tanaka, and H F DeLuca
September 1976, Nutrition reviews,
K Satomura, and Y Seino, and K Yamaoka, and Y Tanaka, and M Ishida, and H Yabuuchi, and Y Tanaka, and H F DeLuca
September 1985, The Journal of biological chemistry,
K Satomura, and Y Seino, and K Yamaoka, and Y Tanaka, and M Ishida, and H Yabuuchi, and Y Tanaka, and H F DeLuca
January 2013, Kidney & blood pressure research,
Copied contents to your clipboard!